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Eligibility for clinical trials in primary Sjo¨gren’s
syndrome: lessons from the UK Primary
Sjo¨gren’s Syndrome Registry
Clare Oni1, Sheryl Mitchell2, Katherine James3, Wan-Fai Ng2,4, Bridget Griffiths2,
Victoria Hindmarsh2, Elizabeth Price5, Colin T. Pease6,7, Paul Emery6,7,
Peter Lanyon8, Adrian Jones8, Michele Bombardieri9, Nurhan Sutcliffe9,
Costantino Pitzalis9, John Hunter10, Monica Gupta10, John McLaren11,
Annie Cooper12, Marian Regan13, Ian Giles14, David Isenberg14,
Vadivelu Saravanan15, David Coady16, Bhaskar Dasgupta17, Neil McHugh18,
Steven Young-Min19, Robert Moots20, Nagui Gendi21, Mohammed Akil22,
Francesca Barone23, Ben Fisher23, Saaeha Rauz23, Andrea Richards24,
Simon J. Bowman1 on Behalf of the UK Primary Sjo¨gren’s Syndrome Registry*
Abstract
Objective: To identify numbers of participants in the UK Primary Sjo¨gren’s Syndrome Registry (UKPSSR)
who would fulfil eligibility criteria for previous/current or potential clinical trials in primary SS (pSS) in order
to optimize recruitment.
Methods: We did a retrospective analysis of UKPSSR cohort data of 688 participants who had pSS with
evaluable data.
Results: In relation to previous/current trials, 75.2% fulfilled eligibility for the Belimumab in Subjects with
Primary Sjo¨gren’s Syndrome study (Belimumab), 41.4% fulfilled eligibility for the Trial of Remicade in primary
Sjo¨gren’s syndrome study (Infliximab), 35.4% for the Efficacy of Tocilizumab in Primary Sjo¨gren’s Syndrome
study (Tocilizumab), 31.6% for the Tolerance and Efficacy of Rituximab in Sjo¨gren’s Disease study
(Rituximab), 26.9% for the Trial of anti-B-cell therapy in pSS study (Rituximab) and 26.6% for the Efficacy
and Safety of Abatacept in Patients With Primary Sjo¨gren’s Syndrome study (Abatacept). If recent measures
of outcome, such as the EULAR Sjo¨gren’s Syndrome Patient Reported Index (ESSPRI) score55 (measure of
patient symptoms) and the EULAR Sjo¨gren’s Syndrome Disease Activity Index (ESSDAI) score55 (measure
of systemic disease activity) are incorporated into a study design, with requirements for an unstimulated
salivary flow>0 and anti-Ro positivity, then the pool of eligible participants is reduced to 14.3%.
1Rheumatology Department, University Hospitals Birmingham NHS
Foundation Trust, Birmingham, 2Rheumatology Department,
Newcastle upon Tyne Hospitals NHS Foundation Trust,
3Interdisciplinary Computing and Complex BioSystems Research
Group, School of Computing Science, Newcastle University,
Newcastle, 4Musculoskeletal Research Group, Institute of Cellular
Medicine & Newcastle NIHR Biomedical Research Centre for Ageing
and Chronic Diseases, Newcastle University, Newcastle upon Tyne,
5Rheumatology Department, Great Western Hospitals NHS
Foundation Trust, Swindon, 6Leeds Institute of Rheumatic and
Musculoskeletal Medicine, University of Leeds, Chapel Allerton
Hospital, 7NIHR Leeds Musculoskeletal Biomedical Research Unit,
Leeds Teaching Hospitals Trust, Leeds, 8Rheumatology Department,
Nottingham University Hospital, Nottingham, 9Department of
Experimental Medicine and Rheumatology, Barts and the London NHS
Trust and Barts and the London School of Medicine and Dentistry,
London, 10Rheumatology Department, Gartnavel General Hospital,
Glasgow, 11Rheumatology Department, NHS Fife, Whyteman’s Brae
Hospital, Kirkcaldy, 12Rheumatology Department, Royal Hampshire
County Hospital, Winchester, 13Rheumatology Department, Royal
Derby Hospital, Derby, 14Rheumatology Department, University
College London Hospitals NHS Foundation Trust, London,
15Rheumatology Department, Queen Elizabeth Hospital, Gateshead,
16Rheumatology Department, Sunderland Royal Hospital, Sunderland,
17Rheumatology Department, Southend University Hospital,
Southend, 18Rheumatology Department, Royal National Hospital for
Rheumatic Diseases, Bath, 19Rheumatology Department,
Portsmouth Hospitals NHS Trust, Portsmouth, 20Rheumatology
Department, Aintree University Hospitals, Liverpool, 21Rheumatology
Department, Basildon Hospital, Basildon, 22Rheumatology
Department, Royal Hallamshire Hospital, Sheffield, 23Centre for
Translational Inflammation Research, University of Birmingham,
Birmingham and 24Department of Oral Medicine, Birmingham Dental
Hospital, Birmingham, UK
Correspondence to: Simon J. Bowman, Rheumatology Department,
Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, UK.
E-mail: simon.bowman@uhb.nhs.uk
*For other collaborators in the UK Primary Sjo¨gren’s Syndrome
Registry, see Acknowledgements section.
Submitted 18 May 2015; revised version accepted 10 September 2015
! The Author 2015 Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com 1
RHEUMATOLOGY 294
C
L
IN
IC
A
L
S
C
IE
N
C
E
 Rheumatology Advance Access published October 27, 2015
 at U
niversity of Bath on N
ovem
ber 5, 2015
http://rheum
atology.oxfordjournals.org/
D
ow
nloaded from
 
Conclusion: The UKPSSR identified a number of options for trial design, including selection on
ESSDAI55, ESSPRI55 and serological and other parameters.
Key words: Sjo¨gren’s, clinical trial, eligibility, registry.
Rheumatology key messages
. This paper provides detailed information on disease phenotype in a large cohort of Sjo¨gren’s patients.
. This paper presents strategies to design clinical trial eligibility criteria in primary SS to optimize recruitment.
Introduction
Primary SS (pSS) is an autoimmune rheumatic disease
characterized by inflammation of the secretory glands lead-
ing to reduced/absent saliva and tear production [1]. It typ-
ically affects women in their middle years. As well as
glandular features, fatigue and joint pains are the common-
est symptoms reported by 7080% of patients and a major
cause of reduced health-related quality of life in pSS [2].
In total, 6070% of patients with pSS have autoantibo-
dies against the Ro +/ La antigens, and these patients are
at risk of developing systemic complications such as sal-
ivary gland swelling, peripheral neuropathy, interstitial
lung disease, arthritis and skin vasculitis [3]. A subset of
pSS patients (circa 25%) with histological evidence of ger-
minal centre formation on minor labial salivary gland
biopsy, often with systemic disease, particularly salivary
gland swelling, hypergammaglobulinaemia, low comple-
ment levels and salivary gland germinal centres, are at
particular risk of developing mucosa-associated lymphoid
tissue Bcell lymphoma [4].
Therapy for pSS is principally symptomatic using artifi-
cial tears and saliva replacement. Pilocarpine can be used
to stimulate residual saliva production. HCQ and/or low
dose prednisolone are often used to treat fatigue and arth-
ralgia and conventional immunosuppressants for patients
with multisystem involvement. None of these conventional
therapies are of proven effectiveness for Sjo¨gren’s-
specific features, and as a consequence there is a major
unmet need for novel therapies.
In recent years, there has been considerable interest in
targeted therapy of pSS using biologic therapies [5]. A trial
of anti-TNF therapy (Trial of Remicade (infliximab) in pSS
(TRIPSS)) did not, however, demonstrate benefit [6].
Rituximab, an anti-B-cell agent, however, has been effect-
ive in combination with conventional chemotherapy in
treating B-cell lymphoma in pSS [7]. Since B-cell hyper-
activity is commonly seen in pSS, Rituximab is a logical
choice to trial in patients with pSS without lymphoma and
has been evaluated for treating fatigue and other disease
features in a number of open-label studies and case series
[8]. Two initial pilot randomized controlled studies (RCTs)
demonstrated benefit in fatigue and global health and in
improving salivary flow and extraglandular features [9, 10].
Subsequently, there have been two larger clinical trials,
one in France (Tolerance and Efficacy of Rituximab in
Sjo¨gren’s Disease (TEARS)) [11], whose results have
been published, and one currently taking place in the
UK (Trial of anti-B-cell therapy in pSS (TRACTISS)) [12].
The TEARS study did not meet its primary end point, but
did demonstrate improvements in fatigue from 6 weeks
and dryness from 16 weeks.
An open-label study of 30 patients who received
Belimumab has recently been reported (Efficacy and
Safety of Belimumab in Subjects with Primary Sjo¨gren’s
Syndrome (BELISS)) [13], and RCTs of Abatacept
(NCT02067910) and of Tocilizumab (NCT01782235) are
ongoing (https://www.clinicaltrials.gov).
One challenge in conducting trials of biologic therapies
in pSS is determining eligibility and outcome criteria. A
symptom questionnaire, the EULAR Sjo¨gren’s Syndrome
Patient Reported Index (ESSPRI) [14], has been devised to
measure dryness, fatigue and pain symptoms, and the
EULAR Sjo¨gren’s Syndrome Disease Activity Index
(ESSDAI) to quantify systemic disease activity [15]. Data
has been published identifying the thresholds for an un-
satisfactory level of patient symptoms (ESSPRI 55) and
minimal clinically important improvement (MCII) of 1 point
or 15% and of moderate systemic disease activity
(ESSDAI 55), severe systemic disease activity (ESSDAI
514) and MCII of three points [16]. Initial clinical trial
data has suggested that both ESSPRI and ESSDAI are
sensitive to change [17, 18].
Given the heterogeneity of the patients, it can be a chal-
lenge to determine eligibility criteria that balance a suffi-
cient level of disease activity/severity, as discussed in the
above papers, or other patient stratification requirements
to determine a meaningful clinical improvement, against
the need for sufficiently broad entry criteria to facilitate
recruitment as this is a significant potential barrier to suc-
cessful trial completion [19].
This paper addresses the recruitment component of this
equation. In order to do so we have interrogated the UK
Primary Sjo¨gren’s Syndrome Registry, a cohort of around
700 patients representing clinical practice and recruited
from a combination of district general and teaching hos-
pitals in the UK [20]. In broad terms, the UK Primary
Sjo¨gren’s Syndrome Registry (UKPSSR) represents the
population from which patients would be recruited to clin-
ical trials in the UK (and indeed has been for the
TRACTISS Study [12]) and is therefore particularly suitable
for this analysis. We evaluated available patient data in the
UKPSSR against major eligibility criteria for the above
studies, as well as considering the effect of other combin-
ations of eligibility criteria that may reflect trial design in
the future.
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Methods
Participants
Recruitment to the UKPSSR started in August 2009. Data
was available from 688 participants on 24 June 2013,
when the data was downloaded for this analysis.
Missing data is indicated in the text, with n = 688 used
as the default denominator unless indicated. All partici-
pants fulfilled the AmericanEuropean Consensus Group
(AECG) classification criteria for primary Sjo¨gren’s
Syndrome [21]. The UKPSSR is an human tissue act re-
search database and tissue bank. National Health Service
(NHS) Research Ethics Committee approval was obtained
from National Research Ethics Service (NRES) Committee
North West Haydock for the UKPSSR, to support a wide
range of research projects in primary Sjogren’s syndrome,
including this analysis. All patients provided written in-
formed consent for the UKPSSR.
The following parameters were evaluated: age, sex, cur-
rent medication, ESSPRI and components (dryness, fa-
tigue and pain), patient global assessment (assessed by
the EQ5D visual analogue scale (VAS)), ESSDAI and com-
ponents, Sjo¨gren’s Syndrome Damage Index (SSDI) [22],
anti-Ro/La antibody status, unstimulated salivary flow rate
(usf), disease duration from diagnosis (years), time from
symptom onset (years), IgG and C3 and C4 levels, fibro-
myalgia and comorbidities. For the purposes of this study,
a score of 5/10 on a Likert scale was taken to be equiva-
lent to 50/100 on a VAS.
Trial eligibility criteria evaluated
The UKPSSR data was evaluated against the major eligibility
components of the following trials (see also the above
Introduction section), approximated where necessary to re-
flect the data available. Trial of Remicade in primary
Sjo¨gren’s syndrome (TRIPPS) [6]: AECG+,>50 mm out of
100 VAS of 2 out of 3 of the ESSPRI components (fatigue,
pain and dryness), no immunosuppressive medication or
pilocarpine (HCQ and prednisolone415 mg/day allowed).
TEARS [11]: AECG+, active disease defined as550 mm
out of 100 VAS of 2 out of 4 of the ESSPRI components
and patient global assessment, disease symptom onset
within 10 years and one biologic feature (autoantibodies;
anti-Ro, rheumatoid factor (RF), cryoglobulinaemia, low
complement C3 or C4, raised immunoglobulins, or B2-
microglobulin) or at least one systemic feature or current
parotid gland enlargement (broadly comprising the ESSDAI
components used for this analysis), no immunosuppressive
medication for 4 weeks (but stable dose HCQ, methotrexate,
pilocarpine, prednisolone allowed). TRACTISS [12]: AECG+,
anti-Ro+,55/10 fatigue and oral dryness (ESSPRI global
dryness used instead for this evaluation) on a Likert scale.
If more than 10 years since disease onset, at least one bio-
logic feature (broadly comprising ESSDAI components), usf
rate>0, stable dose of corticosteroid therapy, other im-
munosuppressant medication and/or pilocarpine allowed.
BELISS [13]: AECG+, anti-Ro/La+,51 systemic feature
(taken in this study to be at least one positive clinical
ESSDAI domain score), or, one objective oral/ocular dryness
feature + raised IgG or low C4 (or raised B2 microglobulin) or
monoclonal gammopathy/cryoglobinopathy (taken as a
positive ESSDAI biological domain score), or, disease
duration< 5 years and all three ESSPRI domain scores
>5. Efficacy and Safety of Abatacept in patients with
Primary Sjo¨gren’s Syndrome (ASAPIII) NCT02067910:
AECG+, ESSDAI 55, disease duration47 years, no im-
munosuppressive medication or pilocarpine for 4 weeks, a
stimulated salivary flow (ssf) exclusion  for the purpose of
this paper considered with and without an additional usf =0
exclusion. Efficacy of Tocilizumab in Primary Sjo¨gren’s
Syndrome (ETAP) NCT01782235: AECG+, anti-Ro/La+,
ESSDAI 55, azathioprine and MMF excluded, also new or
dose change in other medications within 28 weeks (con-
sider with or without additional pilocarpine, prednisolone,
disease-modifying anti-rheumatic drug medication exclu-
sions). Potential study designs: AECG+, anti-Ro+, ESSPRI
55, ESSDAI55/7/11/14, usf rate >0, disease duration
since diagnosis<5/<10 years/any, stable therapy allowed/
stopped.
Statistical analysis
Data was analysed using Microsoft Excel for basic de-
scriptive statistics, Statistical Package for the Social
Sciences (SPSS) for most comparative analyses and the
Social Science Statistics website (http://www.socscista-
tistics.com/) for Chi2 analyses. For comparison of distri-
butions between groups, the MannWhitney U test
(independent samples) was used. Chi2 was used for com-
parison of discontinuous variables between groups.
Spearman’s test was used for correlation analysis.
P< 0.05 was taken as significant throughout.
Results
The frequencies of participant characteristics are set out
in Table 1. The frequencies of participants with individual
ESSDAI domain scores of 1 or more as well as of partici-
pants with positive SSDI damage item/domain scores can
be found in supplementary Table S1, available at
Rheumatology Online.
Table 2 presents the frequencies of eligible participants
according to the different trial eligibility criteria. BELISS was
most permissive at 75.2%, with three different ways to
meet eligibility criteria. TEARS and TRIPSS were next,
with almost half of the cohort potentially eligible (46.3%
and 41.4%, respectively), whereas the ETAP, ASAPIII and
TRACTISS protocols would allow between a quarter and
just over a third of the patients potentially to participate
(35.4%, 26.6% and 26.9%, respectively). Although data is
also presented on the lower numbers when excluding spe-
cified medications, these are slightly artificial in that many
patients who wish to participate would likely be able to
come off these medications to meet eligibility criteria.
ESSPRI and ESSDAI thresholds and other core
parameters
Table 3 presents data for a potential study that varies a
number of key parameters, including anti-Ro+/ as the
www.rheumatology.oxfordjournals.org 3
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key serological item, usf >0 or =0, an ESSDAI score meet-
ing the cut-off for moderate disease of55 [14], or higher
thresholds and an ESSPRI symptom score55 recom-
mended as the minimum threshold for clinical trials [14] or
with 2/3 items55, and by different maximum disease dur-
ation cut-offs. In total, 14.4% of the participants meet these
potential criteria based on anti-Ro+, ESSPRI 55, ESSDAI
55 and usf >0. If the serological component of the eligibil-
ity criteria (i.e. a requirement to be anti-Ro+) is not obliga-
tory, then 16.4% of participants meet the criteria (Table 3). If
neither pilocarpine, nor DMARD therapy is allowed, then the
eligible percentage falls to 9.2%. If the ESSDAI threshold is
increased above 5 and/or disease duration reduced below
5 years, then the eligible numbers falls substantially.
Alternatively, if only ESSPRI 55 and ESSDAI 55 alone
are mandatory, then 27.2% of participants become eligible.
Table 4 sets out data using an alternative approach in
which patients are selected according to only one param-
eter (ESSPRI55, ESSDAI55, anti-Ro + or usf >0) and to
examine whether there is enrichment for any of the other
parameters in the group positive for the original param-
eter. There is modest mutual enrichment for ESSPRI 55
and ESSDAI 55 (P = 0.01), and there is a correlation be-
tween the two scores (n = 678, Spearman correlation
rho = 0.142, P< 0.001. Anti-Ro patients are more likely
to have an usf >0 and vice versa (P = 0.04).
Serology
In total, 87.1% of the cohort are anti-Ro + (missing n = 4). If
this is extended to allow alternative serological features
(low complement levels or raised IgG levels), this in-
creases to 89.1%. The UKPSSR does not include
TABLE 1 Database patient demographics, n = 688
Age, years, mean (S.D.) 58.5 (12.5)
% patients<18 0
% patients>80 1.7
Sex, M %; F % 5.4; 94.6
Current medications, %
HCQ 38.5
CYC 0.15
AZA 3.5
Mycophenylate 1.5
MTX 2.6
Rituximaba 0.9
Oral corticosteroids 10.9
Pilocarpine 7.5
HCQor oral corticosteroid 46.8
DMARD (AZA, MTX, SZP, LEF, CYA, MMF, TAC) 8.7
Pilocarpine or a DMARD 15.4
Rituximab/CYC/IVIG/Chlorambucil/
chemotherapy/other
1.7
ESSPRI
Mean dryness score (S.D.) 6.0 (2.6)
Mean fatigue score (S.D.) 5.5 (2.7)
Mean pain score 4.5 (3.0)
Mean ESSPRI score 5.3 (2.2)
Dryness score55, % 71.5
Fatigue score55, % 64.3
Pain score55, % 51.5
Mean ESSPRI score55, % 60.2
2/3 ESSPRI55, % 65.1
Fatigue score55 and dryness score55, % 54.7
ESSDAI
Mean ESSDAI 4.8 (4.9)
ESSDAI =0, % 17.3%
ESSDAI55, % 41.7%
ESSDAI57, % 28.9%
ESSDAI59, % 17.3%
ESSDAI511, % 11.8%
ESSDAI514, % 5.1%
ESSPRI55 and ESSDAI55, % 27.2%
SSDI oral score, mean (S.D.) 1.59 (1.14)
SSDI ocular score, mean (S.D.) 0.58 (0.73)
SSDI systemic score, mean (S.D.) 0.41 (0.73)
Mean EQ5D global score 60.3
Anti-Ro +, % 87.1
Anti-La +, % 70.8
Anti-La + but anti-Ro, % 0.6
Fibromyalgia, % 9.0
Either anti-Ro+/anti-La+/high IgG/lowC3/lowC4,
%
89.1
usfrate>0mls/15 min, % 63.1
Unstimulated flow rate>1.5mls/15 min, % 19.8
Schirmer I test (average of both eyes)> 0mm/5
min, %
77.8
Schirmer I test (average of both eyes)> 5mm/5
min, %
36.8
Disease symptom duration, mean (S.D.), years 6.7 (6.0)
Disease duration<5 years, % 50.2
Disease duration<10 years, % 76.1
Low C3, % 6.7
Low C4, % 21.2
Lymphoma, % 6.8
Other malignancy, % 5.5
Mean IgG level 16.5
IgG>16, % 44.3
aNo patients on etanercept or infliximab. ESSPRI: EULAR
Sjo¨gren’s Syndrome Patient-Reported Index; ESSDAI:
EULAR Sjo¨gren’s Syndrome Disease Activity Index; SZP:
Sulfasalazine EN; TAC: Tacrolimus; CYA: Ciclosporin.
TABLE 2 Number of patients from the database eligible
for the following trials, total n = 681
N (%)
ABATACEPT (ASAPIII) 181 (26.6)
no medications allowed 75 (11.0)
usf =0 118 (17.3)
no medications allowed and usf =0 46 (6.8)
BELIMUMAB (BELISS) 512 (75.2)
RITUXIMAB (TEARS (FRANCE)) 315 (46.3)
INFLIXIMAB (TRIPSS) 282 (41.4)
If pilocarpine, MTX, AZA or
MMF allowed
339 (49.8)
RITUXIMAB (TRACTISS (UK)) 183 (26.9)
TOCILIZUMAB (ETAP) 241 (35.4)
no medications allowed 99 (14.5)
ASAPIII: Efficacy and Safety of Abatacept in Patients With
Primary Sjo¨gren’s Syndrome; ETAP: Efficacy of Tocilizumab
in Primary Sjo¨gren’s Syndrome; BELISS: Efficacy and Safety
of Belimumab in Subjects With Primary Sjo¨gren’s Syndrome;
TEARS: Tolerance and Efficacy of Rituximab in Sjo¨gren’s
Syndrome; TRACTISS: Trial of Anti-B-Cell Therapy in pri-
mary Sjo¨gren’s Syndrome; TRIPSS: Trial of Remicade in
Primary Sjo¨gren’s Syndrome; usf: unstimulated salivary
flow rate; N: number.
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sufficiently detailed information about RF and ANA, but in
the Sjo¨gren’s International Collaborative Clinical Alliance
(SICCA) cohort, circa 1% of participants were anti-Ro,
anti-La-, ANA 5320 + and RF + (Shiboski C & Shiboski S,
personal communication), which if applied to the
UKPSSR, would bring the total numbers of participants
with a relevant serological abnormality to just over 90%.
In this present study of the UKPSSR cohort, the mean
ESSPRI (missing n = 9) among 593 anti-Ro + participants
with complete data for both ESSPRI and anti-Ro was 5.25
(S.D.= 2.23) (median = 5.33, interquartile range 3.677) and
among 82 anti-Ro participants with complete data was
5.91 (S.D.= 2.10) (median = 6.33, interquartile range
4.337.33) (P = 0.011; MannWhitney U test). The mean
ESSDAI (missing n = 1) among 595 Ro + participants with
complete data was 5.07 (S.D.= 5.12) (median= 4, interquar-
tile range 17) and among 88 Ro participants was 3.31
(S.D.= 2.95) (median = 3, interquartile range 05) (P = 0.006;
MannWhitney U test).
Unstimulated salivary flow of zero and disease
duration
In this study, 434/688 (63.1%) of participants had an usf >
0. The mean of the ESSPRI dryness Likert score was
lower at 5.53 (S.D.= 2.53) (median = 6, interquartile range
48) in 426 participants, with an usf > 0, compared with
TABLE 3 Number of patients from the database eligible for a theoretical study
Stable therapy allowed
Disease Duration, N (%)
Ro+, ESSPRI55, usf>0 Any <10 years <5 years
ESSDAI55 99 (14.4) 79 (11.5) 49 (7.1)
ESSDAI57 66 (9.6) 57 (8.3) 35 (5.1)
ESSDAI59 39 (5.7) 32 (4.7) 18 (2.6)
ESSDAI511 26 (3.8) 20 (2.9) 10 (1.5)
ESSDAI514 12 (1.7) 11 (1.6) 7 (1.0)
Ro+, ESSDAI55, usf>0 ESSPRI 2/355a 111 (16.1) 85 (12.4) 51 (7.4)
Ro+, ESSDAI55, usf>0, ESSPRI any 151 (21.9) 125 (18.2) 81 (11.8)
ESSDAI55, usf>0, ESSPRI55 with Ro+/ 113 (16.4) 84 (12.2) 54 (7.8)
ESSDAI55, ESSPRI55, Ro+/, usf50 187 (27.2) 134 (19.5) 85 (12.4)
Ro+, ESSPRI55, ESSDAI 55, usf> 0, no pilocarpine 90 (13.1) 73 (10.6) 46 (6.7)
Ro+, ESSDAI 55, usf>0, ESSPRI55, no pilocarpine or DMARD 82 (11.9) 63 (9.2) 33 (4.8)
Data presented here according to ESSPRI>5 (aor 2/3 components>5 where indicated), ESSDAI score, disease duration and,
where indicated, whether Ro+/, whether usf>0 or not and/or whether current pilocarpine or DMARD therapy is allowable.
DMARDs are AZA, MTX, SZP, LEF, CYA, MMF, TAC. ESSPRI: EULAR Sjo¨gren’s Syndrome Patient-Reported Index; ESSDAI:
EULAR Sjo¨gren’s Syndrome Disease Activity Index; usf: unstimulated salivary flow rate; SZP: Sulfasalazine EN; TAC:
Tacrolimus; CYA: Ciclosporin.
TABLE 4 Numbers of participants per category based on selecting by the parameter listed in the left-hand column
Subgrouped parameter
Selected parameter ESSPRI55 ESSDAI55 Anti-Ro+ Usf>0
ESSPRI55; n = 408409 — 186/408 (45.6%) 352/408 (86.3%) 249/409 (60.9%)
ESSPRI<5; n = 267270 — 94/270 (34.8%) 241/267 (90.3%) 176/270 (65.2%)
Chi2 — P = 0.01a P = 0.12 P = 0.26
ESSDAI55; n = 280287 186/280 (66.4%) — 256/287 (89.2%) 177/287 (61.7%)
ESSDAI<5; n = 396400 222/398 (55.8%) — 339/396 (85.6%) 257/400 (64.3%)
Chi2 P = 0.01a — P = 0.17 P = 0.49
Anti-Ro+; n = 593596 352/593 (59.4%) 256/595 (43.0%) — 366/596 (61.4%)
Anti-Ro; n = 8288 56/82 (68.3%) 31/88 (35.2%) — 64/88 (72.7%)
Chi2 P = 0.12 P = 0.17 — P = 0.04a
Usf>0; n = 425434 249/425 (58.6%) 177/434 (40.8%) 366/430 (85.1%) —
Usf =0; n = 253254 160/254 (63.0%) 110/253 (43.5%) 230/254 (90.6%) —
Chi2 P = 0.26 P = 0.49 P = 0.04a —
(ESSPRI>5 or<5; ESSDAI>5 or<5; anti-Ro+/-; usf >0 or =0) and then subgrouping by each of the parameters individually.
Missing data: ESSPRI n = 9, ESSDAI n = 1, anti-Ro n = 4, usf n = 0. aSignificant at P = 0.05. ESSPRI: EULAR Sjo¨gren’s
Syndrome Patient-Reported Index; ESSDAI: EULAR Sjo¨gren’s Syndrome Disease Activity Index.
www.rheumatology.oxfordjournals.org 5
Eligibility for clinical trials in PSS
 at U
niversity of Bath on N
ovem
ber 5, 2015
http://rheum
atology.oxfordjournals.org/
D
ow
nloaded from
 
6.78 (S.D.= 2.43) (median = 7, interquartile range 59)
among 254 participants with an usf of zero (P< 0.001;
MannWhitney U test) (missing n = 8).
The mean ESSPRI score overall (which also includes
fatigue and pain), however, was similar at 5.21 (S.D.=
2.22) (median = 5.33, interquartile range 3.677) among
425 participants with an usf > 0, compared with 5.52
(S.D.= 2.21) (median = 5.67, interquartile range 47.08)
among 254 with an usf =0 (Mean ESSPRI missing n = 9)
(P = 0.129; MannWhitney U test).
The mean ESSDAI score was also similar at 4.65 (S.D.=
4.74) (median = 3, interquartile range 1.757) among 434
participants with an usf > 0, compared with 5.11 (S.D.=
5.22) (median = 4, interquartile range 17) among 253 par-
ticipants with an usf =0 (P = 0.41; MannWhitney U test).
The mean disease duration (missing n = 29) was slightly
lower at 6.27 years (S.D.= 5.81) (median = 4.67, interquar-
tile range 1.678.67) among 415 participants with an usf
>0 compared with 7.43 (S.D.= 6.12) (median = 5.92, inter-
quartile range 2.4411.46) among 244 participants with an
usf of zero (P = 0.01; MannWhitney U test).
Examining this the other way round, common eligibility
thresholds that can be arbitrarily proposed for maximum
disease duration (from formal medical diagnosis) are<5
years or<10 years. The rationale is that patients with ear-
lier disease arguably have more activity and less damage.
Table 5 sets out the frequencies of patients with an
ESSPRI 55, ESSDAI 55, anti-Ro + and usf >0 in these
three groups. The only significant difference is that patients
with a disease duration of 10 years or more have a greater
likelihood of an usf =0 (Chi2 = 9.99, P = 0.007) and, in keep-
ing with this disease, duration correlates inversely with usf
(Spearman correlation rho =0.108, P = 0.006).
Discussion
There is a huge unmet need for novel therapies for pSS
[23]. A number of clinical trials of such therapies are now
underway or planned [5]. Designing clinical trials in the
absence of proven therapy, however, is a challenge.
There has been significant progress on developing out-
come tools for pSS such as the ESSPRI [14] and
ESSDAI [15] and the definition of MCII and the patient-
acceptable symptom state (PASS) [16]. This study inter-
rogates the UKPSSR in order to address the question of
how various eligibility criteria affect potential recruitment
numbers.
Anti-Ro and anti-La antibodies are the key antibodies
associated with pSS. In most cohorts, circa 7080% of
patients are positive for anti-Ro/La [3, 24]. The UKPSSR
has a higher percentage at 87.7%. This most likely reflects
the fact that this pragmatic study recruits participants from
around the UK, where the majority of units do not have
access to minor labial salivary gland biopsy, thus requiring
the presence of these antibodies to fulfil AECG criteria,
leading to a bias in recruitment towards anti-
Ro+ participants [20]. The rationale for only including par-
ticipants with anti-Ro + (and/or other serological positivity)
is that this group is more homogeneous and likely to rep-
resent those with a clear-cut diagnosis, those having under-
lying immune-based disease, and those with systemic
disease, although in this study, the percentage of anti-
Ro+ patients with an ESSDAI 55 did not differ statistically
from the percentage of patients who were anti-Ro (43.0%
versus 35.2% Chi2 P = 0.17). Including patients lacking anti-
Ro or anti-La antibodies, but who are ANA + or RF + or have
raised immunoglobulins or low complement levels, is an
alternative potential strategy to broaden the serology-
positive group. This current study was not able to evaluate
ANA and RF directly, but in other previously reported co-
horts, ANA positivity was at 8090% of participants [3, 24],
although this is dependent on the definition of ANA positiv-
ity. RF positivity was less common [3, 24].
With regard to glandular function, particularly salivary
function, the goal is to identify participants who maintain
sufficient residual function in order to respond to therapy,
and in whom the mechanism of reduced saliva function is
due to inflammation rather than atrophy or fibrosis. Labial
gland biopsy and/or salivary gland ultrasound may be
helpful in clarifying the level of structural changes in the
glands [25, 26]. ssf appears to reflect inflammation more
closely than usf [25]. ssf can be measured using several
techniques (e.g. using citric acid solution, by rolling a me-
tallic or glass ball, or by chewing on paraffin wax), and a
ssf of zero is an indicator that there is glandular damage
that may not respond to therapy. An usf, however, can be
easily measured during a routine clinic, and may therefore
lend itself more easily to initial screening of patients with
potentially absent ssf.
TABLE 5 Numbers of participants grouped by disease duration (<5 years, 5 to <10 years and>10 years)
<5 years (n =327330) 5 to<10 years (n = 170171) 510 years (n =157158) Chi2 between groups
ESSPRI55 185/330 (56.1%) 103/171 (60.2%) 103/158 (65.2%) Chi2 = 3.77, P = 0.15
ESSDAI55 139/330 (42.1%) 71/171 (41.5%) 65/157 (41.4%) Chi2 = 0.03, P = 0.99
Anti-Ro+ 291/328 (88.7%) 158/170 (92.9%) 139/158 (88.0%) Chi2 = 2.76, P = 0.25
Usf>0a 216/330 (65.5%) 116/171 (67.8%) 83/158 (52.5%) Chi2 = 9.99, P = 0.007
Data was available from 659 particpants (missing disease duration data n = 29) and is set out for ESSPRI, ESSDAI, anti-Ro
antibody status and usf. Numbers with available data are indicated in the Table. aDisease duration correlated inversely with usf
(n = 659, Spearman correlation rho =0.108, P = 0.006). ESSPRI: EULAR Sjo¨gren’s Syndrome Patient-Reported Index;
ESSDAI: EULAR Sjo¨gren’s Syndrome Disease Activity Index.
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Disease duration is also potentially relevant. The as-
sumption is made, based on the rheumatoid arthritis
model [27], that earlier disease is more likely to be due
to active inflammation, and later disease is more likely to
reflect damage (or at least a lower amenability to immu-
nomodulation). In this study, there was a statistically sig-
nificant (but modest) inverse correlation between disease
duration and usf (Spearman correlation rho = 0.108,
P = 0.006). There was a statistically significantly lower pro-
portion of participants with a usf >0 in participants with a
disease duration of<10 years compared with those with a
disease duration of 10 or more years (66.3% compared
with 52.5% (Chi2 = 9.72, P = 0.002)). Although these differ-
ences are statistically significant, this is largely due to the
big sample size, and the clinical effect size is small.
Nevertheless, this data would potentially support a cut-
off of<10 years for trial entry. Over half of the participants
with a disease duration of 10 years or more still, however,
have a usf >0, so an alternative option is to set the eligi-
bility criteria around salivary flow directly rather than dis-
ease duration.
With regard to patient symptoms and systemic disease,
the ESSPRI and ESSDAI are now regarded as the gold-
standard measures, and recent data identifies an ESSDAI
threshold score of 5 or more to identify moderate or
severe systemic disease activity [14]. For the ESSPRI, a
score of 5 or more is above the PASS. In total, 59.6% of
participants in the UKPSSR had an ESSPRI of 5 or more,
and 41.7% had an ESSDAI of 5 or more. There is no
higher threshold for ESSPRI, but an ESSDAI of 14 or
more (5.1% of participants) is defined as severe systemic
disease. What is clear from these percentages is that
choosing an ESSDAI eligibility threshold above 5 is likely
to be challenging from the perspective of recruitment due
to the rapid fall-off in numbers of eligible participants as
the ESSDAI threshold rises above 5. An increase in the
eligibility threshold from an ESSDAI 5 5 to an ESSDAI
57, for example, means a drop in potentially eligible par-
ticipants from 41.7% to 28.9% of the cohort. At an
ESSDAI of 57, in those patients where a raised IgG
level is contributing two points to the total ESSDAI score
through the biological domain (maximum domain score
=2), this may need to be considered in terms of the clinical
relevance of an improvement in the total ESSDAI score.
Recruiting participants with 2 out of 3 ESSPRI compo-
nents with a score of 5 or more instead of a mean ESSPRI
score of 5 or more generates a small increase in eligible
participants from 59.6% to 65.1%. Arguably, this option
increases complexity in assessing outcome, although it
may helpfully link outcome to individual patient character-
istics. Validation of the PASS and the minimal clinically
MCII level has been performed on the total ESSPRI
score not on a 2/3 component improvement, which may
limit this option.
Although there are some statistical relationships be-
tween ESSPRI, ESSDAI, anti-Ro antibodies and usf (as
set out in Table 4), again the rho values are modest,
with none of them so striking as to offer a clear strategy
for selecting one parameter so as to also enrich for
another. Medication is a potential eligibility criterion. In
total, 38.5% of UKPSSR participants were taking HCQ.
Excluding patients on this medication, or requiring a
lengthy period off this medication prior to recruitment
(e.g. [mt]4 weeks), is likely to have an impact on recruit-
ment. Pilocarpine, oral corticosteroids and DMARDs are
each taken by 7.510.9% of participants, and while each
of these might appear to be a relatively small number,
cumulatively this becomes significant.
Evaluating the trials to date, TRIPPS selected essen-
tially on ESSPRI alone, with modest restriction in
medications. TEARS and TRACTISS add a requirement
for anti-Ro + and a usf >0, and (as a consequence) eligi-
bility falls to 31.6% and 26.9%, respectively. ETAP and
ASAPIII focus on the ESSDAI and require an ESSDAI
score of at least 5 (moderate systemic disease activity)
with anti-Ro + required for ETAP. BELISS, which also in-
cludes anti-Ro+, offers an interesting way of maximizing
recruitment by offering different routes to eligibility, includ-
ing ESSDAI, ESSPRI or objective dryness. In a theoretical
study that incorporates ESSDAI 55, the percentage eli-
gible reduces to 14.3%. If eligibility is based around
ESSDAI 55, without reference to ESSPRI (Ro+, usf >0),
then 21.9% become eligible.
The JOQUER trial of HCQ versus placebo in pSS [28]
offers an alternative approach, which is essentially to
accept nearly all patients with pSS, subject only to
some limitations around current and previous therapies.
This has the benefit of optimizing recruitment, but is po-
tentially more challenging in demonstrating efficacy,
which (as discussed here) is also a major consideration,
particularly for new expensive biologic therapies.
In terms of putting this all together as a general starting
proposal for trial eligibility based around optimizing re-
cruitment, the following could be considered, based on
the UKPSSR Registry data: to require anti-Ro antibody
positivity for trials requiring patient homogeneity, or,
where this is less critical but where serological evidence
of immune activity is still desirable, to offer serological
criteria that are as broad as possible (but still requiring
the AECG criteria for trial entry) e.g. potentially to allow
any of Ro+, La+, ANA+, RF+, IgG >16, or low C3 or C4;
for studies where residual glandular function is important,
to exclude participants with a ssf =0 and to consider using
usf as a means of pre-screening for suitable individuals in
a routine clinic; allow stable medication for 4 weeks before
the baseline visit wherever possible.
Disease duration does not appear to be an absolutely
critical restriction, but<10 years from formal diagnosis
could be considered (recognizing the limitations of this).
Consider selecting either for ESSPRI 55 or ESSDAI 55
for outcome, whereas recruitment based on having both
an ESSDAI 55 as well as an ESSPRI 55 may be challen-
ging because it reduces the potential pool of participants by
circa 60%. With a number of clinical trials taking place over
the next few years, further clarification and refinement of
these eligibility criteria will be likely as data from these fur-
ther trials becomes available (in terms of setting criteria to
optimize the likelihood of demonstrating improvement in the
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outcome measures and also of balancing this against opti-
mizing recruitment, as evaluated in this study).
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